The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to consider dose
Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action
Assay Identifies High-Potency Product Lots Associated with Enhanced Survival
New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality